Drug Discovery

CASI Pharmaceuticals in-licenses rights to novel anti-CD38 monoclonal antibody program from Black Belt Therapeutics

CASI Pharmaceuticals has announced the signing of a license agreement for exclusive worldwide rights to the investigational anti-CD38 monoclonal antibody (Mab) TSK011010 program from Black Belt Therapeutics.

SK Biopharmaceuticals, twoXAR collaborate to develop treatments for NSCLC

SK Biopharmaceuticals has collaborated with an artificial intelligence (AI)-driven biopharmaceutical firm twoXAR for the discovery and development of first-in-class treatments for non-small cell lung cancer (NSCLC).

LabCorp to buy Envigo’s non-clinical research services business in $485m deal

LabCorp’s Covance Drug Development segment is set to acquire Envigo’s non-clinical research services business, while Envigo’s Research Models Services business will purchase the Covance Research Products business.

DNDi, Atomwise collaborate to advance drug development using AI for neglected diseases

Atomwise, a biotech company using artificial intelligence (AI) for drug discovery, and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization working to deliver new treatments for neglected diseases, announced that promising drug-like compounds have been discovered in a program to develop first-in-class treatments for Chagas disease.

Gilead, insitro collaborate to develop therapies for nonalcoholic steatohepatitis

Gilead Sciences has entered into a partnership with insitro for the discovery and development of novel therapies for nonalcoholic steatohepatitis (NASH), a chronic form of liver disease.

Allele, SCM Lifescience sign joint research and development agreement to develop iPSC-based diabetes treatment

San Diego-based Allele Biotechnology and Pharmaceuticals, Inc., officially announced a joint research and development agreement with South Korea’s SCM Lifescience Co., Ltd., for the development of diabetes therapies using pancreatic beta cells derived from induced pluripotent stem cells (iPSCs).

Catalent to buy CDMO Paragon Bioservices for $1.2bn

Catalent has agreed to acquire contract development and manufacturing organization (CDMO), Paragon Bioservices, in a deal valued at around $1.2bn.

Dr. Reddy’s Laboratories announces acquisition of ANDA portfolio

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the U.S.

AAV gene therapy company AskBio secures $235m investment

Asklepios BioPharmaceutical (AskBio) has secured an investment of $235m to accelerate its business of developing and manufacturing Adeno-Associated Virus (AAV) gene therapies for rare and generally untreatable genetic disorders.